Supported by Over $1 Billion in Investment, PCI Pharma Services Unveils Major Expansion of U.S. Sterile Fill-Finish and Drug–Device Combination Capabilities
PCI Pharma Services has unveiled an extensive series of infrastructure investments aimed at significantly strengthening its sterile fill-finish capabilities and advanced drug delivery solutions, marking a major step forward in its long-term growth and innovation strategy. As a leading global contract development and manufacturing organization (CDMO), PCI is positioning itself to meet the evolving demands of pharmaceutical and biotechnology companies, particularly as the industry increasingly prioritizes supply chain resilience and localized manufacturing in the United States.
These latest developments form part of a broader investment commitment exceeding $1 billion across PCI’s operations in the U.S. and Europe. The initiative reflects the company’s ambition to provide fully integrated, end-to-end solutions spanning drug product development, clinical trial supply, commercial-scale manufacturing, and drug-device combination assembly. By enhancing both capacity and technological sophistication, PCI aims to deliver seamless support to its partners from early-stage development through to global product launch.
A central pillar of this investment strategy is a $100 million expansion project at PCI’s San Diego campus. This site will be equipped with a high-speed isolator-based filling line specifically designed for ready-to-use (RTU) prefilled syringes and cartridges. Expected to become operational in the first half of 2028, the new line will more than double the site’s current syringe and cartridge filling capacity. It will also represent the second isolator fill-finish line at the San Diego facility, which already plays a critical role in PCI’s manufacturing network.
The San Diego campus currently supports the production of more than 45 FDA-approved products and offers a wide range of advanced capabilities. These include large-scale aseptic filling for injectable formats such as prefilled syringes and cartridges, as well as specialized expertise in complex modalities like oligonucleotides, peptides, and highly potent compounds. Additionally, the site is equipped to handle sophisticated formulations, including nanoparticles, messenger RNA (mRNA), monoclonal antibodies, and protein-based therapeutics. Its lyophilization capabilities further enhance its ability to manage sensitive biologic products that require precise handling and stabilization.
In parallel, PCI is making substantial upgrades to its Bedford, New Hampshire campus, where a bespoke, GMP-ready isolator vial filling and lyophilization line is being commissioned. This advanced system, which is set to begin full-scale production imminently, is designed to deliver high throughput and operational efficiency. It will be capable of processing batch sizes of up to 300,000 vials at a speed of 400 units per minute, resulting in an annual production capacity of approximately 33 million vials. This makes it one of the most robust and technologically advanced sterile fill-finish setups in the United States.
The Bedford facility will also introduce a customer-dedicated high-potent sterile fill-finish line, a unique offering within the U.S. market. This specialized capability is expected to support the growing demand for handling highly potent active pharmaceutical ingredients (HPAPIs), which require stringent containment and safety measures during manufacturing. By investing in such targeted infrastructure, PCI is addressing the increasing complexity of modern drug development, particularly in oncology and other therapeutic areas where high-potency compounds are prevalent.
Across both the San Diego and Bedford sites, PCI has also implemented state-of-the-art automated visual inspection (AVI) systems. These technologies are essential for ensuring product quality and regulatory compliance in sterile manufacturing environments. Collectively, PCI’s U.S.-based AVI infrastructure is capable of supporting more than 70 million prefilled syringes and cartridges and 40 million vials annually, meeting the rigorous standards expected by global pharmaceutical manufacturers and regulatory authorities.
Beyond sterile fill-finish, PCI is also expanding its capabilities in drug-device combination assembly and packaging. In collaboration with leading device manufacturers, the company is enhancing its infrastructure at its campuses in Philadelphia, Pennsylvania, and Rockford, Illinois. These upgrades, which are being rolled out in phases over the next six months, are designed to significantly increase capacity and scalability for autoinjector and combination product assembly.
Looking ahead to 2027, PCI plans to add a third autoinjector assembly line, which will bring its total U.S. capacity for autoinjector and device assembly to more than 250 million units per year. These high-speed assembly lines feature multi-device tooling technology and flexible configurations, enabling the company to support a wide range of device formats and customer requirements. In addition, a dedicated prefilled syringe safety device line will provide integrated labeling and secondary packaging solutions, further streamlining the manufacturing process.
The Philadelphia and Rockford sites also serve as PCI’s U.S. Packaging Centers of Excellence, offering extensive capabilities for both oral solid dose and injectable products. These GMP-compliant facilities are equipped with significant cold chain storage capacity and can be rapidly deployed to support programs at various stages of development. Available capacity across the two sites includes the ability to handle approximately 40 million blister units, 70 million bottles, and 75 million vials annually, underscoring PCI’s ability to support large-scale commercial operations.
Complementing its manufacturing and packaging expansions, PCI is investing in dedicated Development Centers of Excellence (CoEs) in Bedford, New Hampshire, and León, Spain. These centers are designed to provide comprehensive development support across a wide range of modalities, including biologics and small molecules. Their capabilities will encompass formulation development, analytical testing, lyophilization, and drug-device combination development, as well as specialized areas such as long-acting injectables and ophthalmic products.
The CoEs will support both highly potent and non-potent compounds and will accommodate multiple presentation formats, including vials, prefilled syringes, and cartridges. The Bedford Development CoE is expected to become operational in May, followed shortly by the León facility in June. Together, these centers will play a critical role in accelerating product development timelines and enabling seamless transitions from development to manufacturing.
Salim Haffar, CEO of PCI Pharma Services, highlighted the broader industry context driving these investments. He noted that the pharmaceutical sector is at a pivotal moment, with companies increasingly seeking reliable U.S.-based partners that can deliver scale, speed, and a proven track record of quality and regulatory compliance. By investing heavily in infrastructure and capabilities, PCI aims to position itself as a trusted partner for the development and commercialization of next-generation therapies.
Overall, PCI’s multi-faceted investment strategy reflects a clear commitment to innovation, capacity expansion, and operational excellence. By strengthening its domestic manufacturing footprint and enhancing its global capabilities, the company is well-positioned to support the growing demand for advanced drug products and delivery systems. Ultimately, these efforts are aligned with a broader goal shared across the industry: ensuring that life-changing therapies reach patients efficiently, safely, and at scale.
About PCI Pharma Services
PCI is a world-leading CDMO providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the healthcare services business. The company currently has 38 sites across seven countries (United States, Canada, United Kingdom, Ireland, Germany, Spain and Australia), and over 7,500 employees working to bring life-changing therapies to patients.
Leading technology and continued investment enable PCI Pharma Services to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and commercialization. Its clients utilize PCI as an extension of their business, and a collaborative partner with the shared goal of improving patients’ lives.
Source Link:https://www.businesswire.com/
